Court Grants Ciphergen Request to Transfer HDC Patent Suit to California Court
Health Discovery Corporation’s patent-infringement suit against Ciphergen will be transferred from Texas to California, according to recent court documents.
HDC filed suit against Equbits and Ciphergen last June in the US District Court for the Eastern District of Texas for allegedly infringing its support vector machine technology [BioInform 06-30-06].
Ciphergen filed a countersuit in September, along with a request for a change of venue to the US District Court for the Northern District of California because it neither resides nor conducts business in the Texas district [BioInform 09-22-06].
Last week, the Texas court agreed with Ciphergen that the suit was filed “without sufficient facts to support its contention that venue was proper,” and ruled that “the case was filed in the wrong district.”
The court also ruled against HDC’s argument that the Northern District of California is not a proper venue and ordered that the case be transferred to that district.
HDC and Equbits settled their suit in November [BioInform 11-10-07].
UK’s BBSRC to Fund Three Mathematical Systems Biology Networks
The UK’s Biotechnology and Biological Sciences Research Council this week issued a call for proposals for a project titled “Research Networks: Mathematical Tools for Systems Biology.”
The BBSRC will provide £400,000 ($789,000) over three years to support up to six research networks “that will bring together mathematical scientists and life scientists in order to tackle key challenges in systems biology.”
The closing date for proposals is March 7. Further details are available here.
ADA and Entelos to Award Researchers Access to Type 1 Diabetes PhysioLab
The American Diabetes Association and Entelos said this week that they are accepting applications for access to the Diabetes Research Center, which uses Entelos’ Type 1 Diabetes PhysioLab platform, a computer-based mathematical model of the non-obese diabetic mouse, the primary animal model used to study type 1 diabetes.
The ADA and Entelos agreed last June to jointly develop the DRC, which an Entelos official described as an "in silico research facility" [BioInform 06-16-06].
The DRC is soliciting letters of intent for in silico research projects to be conducted in the second half of 2007. The submissions will be reviewed by an ADA-sponsored scientific review committee. “Applicable projects” will be invited to develop a detailed research plan in collaboration with DRC staff.
Further details are available here.
BioDiscovery Joins Microsoft BioIT Alliance
BioDiscovery said this week that it has joined the BioIT Alliance.
BioDiscovery President Soheil Shams said in a statement that involvement in the Microsoft-led effort will “strengthen our competence in providing cross-platform, integrated software solutions.”
The BioIT Alliance is a group of IT and biotech companies working with Microsoft to advance biomedical information technology.
Other Alliance members include Applied Biosystems, Affymetrix, Agilent, and Accelrys.
GNF Renews License to Ingenuity's Pathways Analysis Software
Ingenuity Systems said this week that the Genomics Institute of the Novartis Research Foundation has renewed and expanded a licensing agreement for its pathway-analysis software.
The licensing deal grants GNF continued use of Ingenuity's Pathway Analysis software for the institute's research in RNA profiling, Ingenuity said. GNF originally licensed the software in 2003.
Financial terms of the agreement were not released.
Japanese Paper Co. to Use Rosetta Resolver for Wood Gene-Expression Analysis
The Oji Paper Company, based in Tokyo, has licensed Rosetta Biosoftware's Resolver gene-expression platform, Rosetta said this week.
Oji plans to use the software to characterize gene-expression profiles of wood-forming tissues in its Forestry Research Institute, which employs biotechnology to study issues such as tree afforestation and paper manufacturing.
FRI researcher Takashi Hibin said the company is collecting gene expression profiles of trees during different phases of growth to study the role of gene regulation in wood-forming tissues.
Differences between the expression profiles could point to "potential biomarkers for high-quality fibers for paper production, which can be effective for silviculture and breeding," Hibin said.
Genedata, ChemAxon Integrate Lead Discovery Software
Genedata said this week that it has integrated its lead-discovery software with ChemAxon’s chemical visualization technology.
The integration will join Genedata’s Hit Profiler software with ChemAxon’s MarinView, and will be used in identifying novel drug candidates.
MarinView is used for visualizing and managing chemical structure information, Genedata said, adding that the integration allows the companies to “evolve their solutions independently, yet maintain interoperability.”
Partek Makes Genomic Suite Affy-compatible for SNP-Association Studies
Statistical analysis software company Partek has made its Genomics Suite compatible with the Affymetrix GeneChip platform for SNP association studies, the company said last week.
The St. Louis-based company said that Partek GS is now the “first commercially available software tool” to achieve GeneChip-compatible status for gene expression, exon expression, chromosomal copy number analysis, regulation analysis, and SNP analysis.
Bayer Technology Services Partners with CHOP on Software for Personalized Drug Dosing
Bayer Technology Services is collaborating with Children’s Hospital of Philadelphia on a research project to develop individualized drug therapies for children, the company said today.
BTS will integrate its PK-Sim pharmacokinetic and pharmacodynamic modeling and simulation techniques with CHOP’s “Pediatric Knowledgebase” — an initiative to create a user-friendly computer interface that will present doctors with patient information and dosing history and use simulations to predict “expected trends in drug plasma concentrations,” the company said.
The end result will allow pediatricians to make drug dosing decisions that are tailored to each patient, BTS said.
The collaboration will “aim to demonstrate the usefulness of physiology-based modeling in guiding dosing decisions.” said Jörg Lippert, Head of the Systems Biology Group of BTS, in a statement.
Achaogen Licenses ACD/Labs Software
Antibacterial compound developer Achaogen has licensed ACD/Labs' Structure Designer and Structure Design Suite, ACD/Labs said this week.
Structure Designer helps chemists evaluate physicochemical properties of compounds, while Structure Design Suite adds prediction algorithms that are trainable with in-house experimental data.
Financial terms of the licensing agreement were not provided.